Osteoporosis in the view of osteoimmunology: common feature underlined by different pathogenic mechanisms by DARJA FLEGAR et al.
PERIODICUM BIOLOGORUM UDC 57:61 
VOL. 117, No 1, 35–43, 2015 CODEN PDBIAD 
 ISSN 0031-5362
 
Osteoporosis in the view of osteoimmunology:  
common feature underlined by different pathogenic 
mechanisms
Abstract
Osteoporosis is a skeletal disorder characterized by low bone mineral 
density and microarchitectural changes with increased susceptibility to frac-
tures, resulting in significant morbidity and mortality. Although it pre-
dominantly affects postmenopausal women, it is now well known that sys-
temic bone loss is a common underlying feature of different metabolic, 
endocrine and inflammatory diseases. Investigations of osteoporosis as a com-
plication of chronic inflammatory conditions revealed immune mechanisms 
behind the increased osteoclast bone resorption and impaired osteoblast bone 
formation. This concept was particularly emphasized after the research field 
of osteoimmunology emerged, focusing on the interaction between the im-
mune system and bone. It is increasingly becoming evident that immune cells 
and mediators critically regulate osteoclast and osteoblast development, func-
tion and coupling activity. Among other mediators, receptor activator of 
nuclear factor-kB ligand (RANKL), receptor activator of nuclear factor-kB 
(RANK) and soluble decoy receptor osteoprotegerin (OPG) form a key func-
tional link between the immune system and bone, regulating both osteoclast 
formation and activity as well as immune cell functions. Excessive produc-
tion of inflammatory mediators exerts autocrine, paracrine and endocrine 
signaling effects on bone remodeling with the net increase in bone resorption 
locally, in diseases primarily affecting joints, bones or surrounding tissues, 
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BMD  – bone mineral density 
BMe  – bone marrow edema 
DKK-1  – Dickkopf-1 
IL  – interleukin 
M-CSF  – macrophage colony-stimulating factor 
MRI  – magnetic resonance imaging 
ODF  – osteoclast differentiation factor 
OPG  – osteoprotegerin 
PGe2  – prostaglandin e2
RANK  – receptor activator of nuclear factor – kB
RANKL  – receptor activator of nuclear factor – kB ligand
TNF  – tumor necrosis factor 
TNFSF11  – tumor necrosis factor (ligand) superfamily, member 11 
TNFRSF11A – tumor necrosis factor receptor superfamily, member 11 
TRAIL  – TNF-related ligand 
TRANCe  – TNF-related activation-induced cytokine 
TRAP  – tartrate-resistant acid phosphatase
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diseases. This brief review particularly focuses on bone pathol-
ogy in rheumatoid arthritis, as one of the most extensively 
studied conditions accompanied by local and systemic inflam-
mation-induced bone loss.
1. INTRODUCTION
Osteoporosis is a systemic skeletal disease which af-fects more than 200 million people and is one of the 
major public health problems (1). It is characterized by 
low bone mass and microarchitectural changes, both 
leading to enhanced susceptibility to bone fractures and 
increased mortality risk (2, 3). Estimated occurrence of 
osteoporosis is 1 in 3 women and 1 in 12 men over the 
age of 50 worldwide, being one of the main risk factors 
for pathologic fractures, mostly involving the lumbar ver-
tebrae, hip, and wrist (4). Primary osteoporosis affects 
postmenopausal women due to estrogen deficiency, and 
elderly women and men through vitamin D insufficiency 
and secondary hyperparathyroidism which contribute to 
bone loss (3). On the other hand, secondary osteoporosis 
is outlined as low bone mineral density (BMD) with in-
creased risk of fractures caused by various factors other 
than aging or postmenopause (5). Therefore, it affects men 
and premenopausal women who have not been typically 
considered at high risk for primary osteoporosis (6). In-
creased understanding of bone metabolism and factors 
that influence bone turnover leads to a better characteriza-
tion of diseases, disorders, treatments and medications that 
decrease bone quality in women and men of all ages (2, 
5). These include various endocrine disorders (such as type 
I and II diabetes, Cushing’s syndrome, hyperthyroidism, 
hyperparathyroidism, hypogonadism and others), meta-
bolic disorders (Marfan syndrome, Gaucher’s disease, 
galactosemia), rheumatologic and inflammatory diseases 
(systemic lupus erythematosus, rheumatoid arthritis, an-
kylosing spondylitis, inflammatory bowel disease), chronic 
diseases (chronic obstructive pulmonary disease, celiac 
disease), neurologic, hematologic and oncologic diseases 
(2-6). It also includes medications such as glucocorticoids, 
anticonvulsants, glitazones, heparine, cyclosporine and 
others. Iatrogenic secondary osteoporosis thus became a 
long-term complication of diseases treated with these 
medications (4, 5). In this brief review we will particu-
larly focus on mechanisms of bone loss associated with 
inflammatory arthritides, characterized by chronic in-
flammatory response as well as periarticular and general-
ized bone loss due to deregulation of bone metabolism – 
bone resorption by osteoclasts and bone formation by 
osteoblasts (7-11).
2. BONE PATHOLOGY IN 
OSTEOPOROSIS
Bone remodeling is a well balanced, continuously on-
going homeostatic process of osteoclast bone resorption 
and osteoblast bone formation, ensuring and adjusting 
bone mechanical properties and its response to metabolic 
needs. Hence, it is regulated by numerous factors like 
hormones, cytokines, chemokines and biochemical stim-
uli, and therefore easily disrupted in different pathological 
conditions (5, 12). Well-coordinated differentiation and 
activation as well as synchronized function of two bone 
cell types, osteoclasts and osteoblasts, is crucial for bone 
homeostasis maintenance.
Osteoblasts are mature, cuboidal, non-proliferating 
cells that synthesize and mineralize bone matrix, and in-
fluence osteoclast differentiation (13, 14). Osteoblast pro-
genitors arise from mesenchymal stem cells found in 
periosteum, bone marrow and circulation, which along-
side of osteoblasts can produce a variety of lineages such 
as adipocytes, chondrocytes, myocytes and hematopoiesis 
supporting cells (15-19). Osteoblastogenesis includes pro-
liferation and differentiation of osteoblast progenitors 
through series of maturational stages to functional, bone 
matrix-secreting osteoblasts. By producing macrophage 
colony-stimulating factor (M-CSF), receptor activator of 
nuclear factor-kB ligand (RANKL) and osteoprotegerin 
(OPG), osteoblasts regulate osteoclast progenitor pool 
size, their differentiation and bone-resorbing activity (14, 
20).
Osteoclasts are large, multinucleated, tartrate-resistant 
acid phosphatase (TRAP)-positive, unique bone-resorb-
ing cells (21-26). They originate from hematopoietic stem 
cells found in bone marrow and circulation. Belonging to 
myeloid monocyte/macrophage lineage, osteoclast pro-
genitors express M-CSF receptor (CD115, cFms) and re-
ceptor activator of nuclear factor-kB (RANK; also known 
as tumor necrosis factor receptor superfamily, member 11, 
TNFRSF11A), activation of which is crucial for their dif-
ferentiation and maturation (27). Excessive bone resorp-
tion is an exclusive consequence of increased osteoclast 
activation, since the ability of macrophages and fibroblasts 
to degrade bone is weak (28). Osteoclasts are critically 
involved in skeletal functions such as bone remodeling, 
fracture repair and pathological bone resorption associ-
ated with inflammatory conditions (29).
Osteoporosis results from an imbalance in bone re-
modeling, where bone resorption predominates over bone 
formation (5, 28). Subsequent changes in bone architec-
ture and a net loss of bone mass make bones weak and 
incapable of bearing physiological load. In the most severe 
cases of osteoporosis even normal physical activities lead 
to pathologic fractures (30). Due to most common forms 
of osteoporosis, the postmenopausal osteoporosis and se-
nile osteoporosis, and well described effects of vitamin D3, 
calcium and other nutritional deficiencies on bone struc-
ture, the disease is usually classified as an endocrine or 
metabolic disorder (4). Studies investigating secondary 
osteoporosis, where chronic inflammatory diseases, re-
gardless of the cause and primarily affected sites, are ac-
companied by systemic bone loss and increased risk of 
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fractures, demonstrated the role of the immune system in 
bone remodeling (12, 27). The notion that the plurality 
of etiological causes of bone loss shares a final step of 
impairing osteoclast and osteoblast coupled activity, 
which is mediated by immune cells and cytokines, cre-
ated the research area of osteoimmunology (4, 31, 32). 
This novel approach offers a new perspective in disease 
pathogenesis considering it an inflammatory disease (4).
3. OSTEOIMMUNOLOGY AND RANKL/
RANK/OPG SYSTEM
The field of osteoimmunology emerged with the dis-
covery that T lymphocytes participate in the regulation 
of osteoclast formation, either by stimulatory or inhibi-
tory effects. As such, the research area of osteoimmunol-
ogy focuses on the functional crosstalk between the im-
mune system and bone, making it a new interdisciplinary 
field with a potential to indicate novel targeted therapies 
in diseases accompanied with inflammation-induced 
bone loss (4).
It has been well demonstrated that osteoclasts could 
be derived from immature macrophages and early hema-
topoietic progenitors (33). Osteoclasts share many histo-
chemical and functional similarities with both tissue and 
inflammatory macrophages, including the property of 
tissue degradation followed by reparation carried out by 
cells of mesenchymal origin, osteoblasts or fibroblasts re-
spectively (34). However, osteoclasts express low levels of 
class II major histocompatibility complex molecules, 
CD14, Fc and complement receptors, and do not serve as 
antigen presenting cells (33).
During recent times, TNF-superfamily ligands and 
their respective receptors have been shown to be a crucial 
link between the immune system and other organ sys-
tems, including bone. One of the major examples that has 
significantly contributed to the development of the field 
of osteoimmunology is the cytokine RANKL, addition-
ally identified as TNF-related activation-induced cyto-
kine (TRANCE), osteoclast differentiation factor (ODF), 
and TNFSF11. RANKL, together with its signaling re-
ceptor RANK and soluble decoy receptor OPG, com-
prises the crucial paracrine system, which regulates osteo-
clast formation and function (35, 36). The RANKL/
RANK/OPG system was originally identified as having 
an important role in immunity, mostly mediated through 
Figure 1. Bone loss in rheumatoid arthritis is caused by the complex interplay between immune and bone cells. Immune cells, includ-
ing macrophages, neutrophils, dendritic cells, and T and B lymphocytes, infiltrate the rheumatoid synovium that is constantly inflamed and 
invades adjacent tissue, resulting in joint destruction. These innate and adaptive immune cells vigorously drive differentiation of osteoclast 
progenitors by producing proinflammatory cytokines and RANKL. In addition, synovial fibroblasts and osteoblasts comprise the cellular com-
ponents of synovial and bone matrix, and contribute to osteoclast formation under inflammatory conditions. The osteoclast-rich portion of hy-
perplastic and highly vascularized synovial membrane, called pannus, destroys bone, whereas enzymes, secreted by neutrophils, synoviocytes and 
chondrocytes, degrade cartilage. Mature osteoclasts, as the final effectors of bone loss, exert their bone-resorbing activity at local and systemic 
levels, which include marginal erosions, subchondral bone loss, periarticular bone loss as well as systemic osteoporosis.
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dendritic cells, and, in parallel, as being a crucial factor 
in the regulation of osteoclast formation and therefore 
bone homeostasis. Mouse knockout models for the 
RANKL/RANK/OPG axis components have empha-
sized and clarified its role and importance in both bone 
and immunity during development, homeostasis and dis-
ease, thereby advancing the field of osteoimmunology 
(27).
RANKL potently stimulates both the formation of 
osteoclasts from progenitor cells and the bone-resorbing 
activity of mature osteoclasts. It is predominantly ex-
pressed as a transmembrane protein on the surface of 
stromal cells, osteoblasts, osteocytes, hypertrophying 
chondrocytes and synovial fibroblasts, but can also be 
secreted in soluble form by other cells like activated T 
lymphocytes. RANKL knockout mice have no osteoclasts 
and exhibit osteopetrosis, but have a normal number of 
monocyte/macrophage lineage cells. They also exhibit 
altered lymph node development, with impaired early B- 
and T-lymphoid cell differentiation, pointing to its im-
portant role in both, bone and immune system homeo-
stasis. A number of hormones, cytokines and 
inflammatory mediators, including vitamin D3, parathy-
roid hormone, prostaglandin E2 (PGE2), interleukin(IL)-1, 
IL-6, IL-7, IL-15, IL-17, IL-21 and IL-22 appear to exert 
their osteoresorptive effect by inducing RANKL expres-
sion in mesenchymal lineage cells (33, 35, 37).
RANK (designated as TNFRSF11A), the biologically 
active signaling receptor for RANKL, is expressed on os-
teoclast progenitors and mature osteoclasts, but also on 
dendritic cells. It has been detected at the RNA level in a 
variety of cell types and tissues (including thymus, mam-
mary glands, prostate, bone marrow, lung, brain, liver and 
skin). RANK is strongly induced by M-CSF, especially 
on osteoclast progenitors. As expected, RANK knockout 
mice exhibit the same phenotype as RANKL knockouts 
(33, 37). Osteoclast differentiation is physiologically trig-
gered by RANKL/RANK binding, in the presence of 
M-CSF, which serves to promote proliferation and sur-
vival of osteoclast progenitor cells (20, 33).
OPG, as a soluble receptor, inhibits osteoclast differ-
entiation by binding RANKL and thus preventing 
RANKL/RANK interaction. Additionally, OPG can also 
bind TNF-related ligand (TRAIL). It is produced by bone 
marrow stromal cells, but also expressed by B lympho-
cytes and dendritic cells. It is proposed that OPG is con-
stantly produced in physiological conditions, thereby 
suppressing RANKL activity, which is supported by the 
finding of severe osteoporosis in OPG knockout mice (33, 
36).
Factors that regulate bone remodeling often act by af-
fecting the balance of RANKL and OPG as a key deter-
minant of the rate of osteoclastogenesis and bone resorp-
tion. Consequently, an increased RANKL/OPG ratio 
results in enhanced osteoclast differentiation and forma-
tion of bone erosions in various pathologic conditions 
such as bone cancers and metastases, rheumatoid arthritis 
and osteoporosis. Cytokines and growth factors which are 
produced at sites of inflammation or released from matrix 
during bone turnover often enhance or modulate the re-
sponse of osteoclasts and their progenitors to RANKL/
RANK stimulation (20, 33).
4. CHRONIC INFLAMMATORY DISEASES 
AND BONE DESTRUCTION
Bone loss as a consequence of chronic inflammation 
represents a serious complication associated with arthritis 
as well as other inflammatory processes such as chronic 
bacterial and viral infections, inflammatory bowel dis-
eases and certain metabolic disorders (38-40). Through 
the production of osteoresorptive mediators (IL-1, IL-6, 
IL-11, IL-17, TNF-a, RANKL, CCL2, CXCL12, etc) by 
inflammatory and immune cells, inflammation creates 
conditions that promote osteoclast differentiation and 
structural damage in arthritis (15, 41-44). Three major 
forms of chronic inflammatory joint diseases are classified 
in clinical practice, depending on their pathogenic mech-
anisms and primary target tissue: osteoarthritis, rheuma-
toid arthritis and spondyloarthritis. The latter includes 
ankylosing spondylitis, psoriatic arthritis, reactive arthri-
tis, arthritis associated with inflammatory bowel disease, 
and juvenile and undifferentiated forms (45, 46). In ad-
dition to arthritis, bone loss as a consequence of chronic 
inflammation represents a key feature of localized bacte-
rial infections of bones or adjacent tissues, including car-
ies, periodontitis or osteomyelitis (31).
Rheumatoid arthritis and periodontal disease are rep-
resentative examples of chronic inflammatory diseases 
with bone loss occurring locally at inflamed sites as well 
as systemically in the form of osteopenia and osteoporosis. 
Chronic inflammation in rheumatoid arthritis is a conse-
quence of an autoimmune disorder primarily affecting 
synovial joints, whereas in periodontal disease the persis-
tent bacterial gingival infection repeatedly triggers im-
mune response. Central to the pathogenesis of rheuma-
toid arthritis is the inflammation of synovial tissue 
followed by joint destruction and ankylosis (45, 46). Peri-
odontitis implies chronic inflammation of tooth support-
ing structures leading to progressive alveolar bone resorp-
tion and tooth loss (4). Unlike rheumatoid arthritis, in 
ankylosing spondylitis inflammation occurs at areas of 
ligament and tendon insertions to bone (entheses), fol-
lowed by progression to joint synovium and, finally, joint 
destruction (45). Periarticular bone mineralization is usu-
ally maintained and accompanied by ossification of in-
flamed entheses and syndesmophite formation, suggest-
ing a disorder pattern of enhanced bone remodeling in 
contrast to the predominance of bone resorption seen in 
rheumatoid arthritis (14, 47).
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In other conditions hallmarked by chronic inflamma-
tion not present near bones, such as inflammatory bowel 
diseases (i.e. Crohn’s disease and ulcerative colitis), celiac 
disease, cystic fibrosis and chronic obstructive pulmonary 
disease, the occurring bone loss is only systemic (12). Dif-
ferent factors, such as bed rest, immobilization, malnutri-
tion and medications (especially glucocorticoid treat-
ment) contribute to pathogenesis of generalized and 
localized osteopenia by separate mechanisms. In parallel, 
inflammation activated immune mechanisms disturb the 
homeostasis of bone remodeling by acting directly on 
bone cells, resulting in increased osteoclast activity and 
excess bone resorption as well as impaired osteoblast func-
tion with insufficient bone formation (1-3, 48).
5. PATHOGENESIS OF INFLAMMATION-
INDUCED BONE LOSS
During inflammatory response, cells of innate and 
adaptive immunity produce various mediators, many of 
which, by autocrine, paracrine and endocrine signaling, 
affect osteoclast and osteoblast differentiation, function 
and migration, leading to an imbalance between bone 
resorption and formation (32). A wide range of proinflam-
matory cytokines (IL-1, IL-6, IL-17, IL-18, TNF-a), 
chemokines (such as CCL2, CCL3, CCL4, CCL5, 
CXCL12), growth factors (vascular endothelial growth 
factor, hypoxia-inducible factors), and apoptotic media-
tors (Fas ligand, TRAIL, ligand for herpesvirus entry 
mediator) are disturbed in arthritis, which directly or in-
directly, through the RANK/RANKL/OPG system, 
promote osteoclastogenesis (49-52). It has been shown 
that even a small rise in the level of systemic inflammation 
can precipitate osteodestruction, leading to fractures and 
disabilities related to arthritis (53). Moreover, the presence 
of generalized bone loss, manifested as lower BMD and 
a higher rate of pathologic fractures, has been observed in 
different forms of arthritides and is associated with disease 
severity (20). Although generalized osteoporosis in arthri-
tis was usually attributed to immobility and glucocorti-
coid treatment, more recent studies suggest that systemic 
osteopenia, as well as periarticular bone loss and mar-
ginal erosions, are caused at least in part by a common 
pathogenic mechanism that involves inflammation-in-
duced increase in osteoclast number and activity (Figure 
1) (54-57).
Apart from systemic bone loss, patients with rheuma-
toid arthritis have significant destruction of affected 
joints. It was traditionally postulated that inflammation 
of synovial tissue, with increased vascularity, hyperplasia 
and accumulation of macrophages, plasma cells, T and B 
lymphocytes, dendritic cells, natural killer cells and mast 
cells, is the major pathogenic event as it invades adjacent 
structures (articular cartilage, cortical bone surface and 
underlying bone marrow) and leads to typical signs and 
symptoms of rheumatoid arthritis (joint pain, stiffness, 
swelling and structural changes) (58, 59). However, ‘syn-
ovio-centric’ model of rheumatoid arthritis has been re-
fined after findings that joint disease spreads well beyond 
synovial tissue inflammation involving other, neighbor-
ing anatomic compartments (including subchondral and 
periarticular bone) (60).
With the advance in magnetic resonance imaging 
(MRI), subchondral bone has been recognized as a site of 
pivotal importance for the inflammatory processes in 
rheumatoid arthritis. Bone marrow involvement in the 
form of MRI-visualized bone marrow edema (BME) is a 
common feature at all stages of the disease, and is associ-
ated with disease activity and, most importantly, with 
future development of bone erosions and poor functional 
outcomes. MRI scans show structural changes, which 
extend into the bone marrow cavity and are linked either 
to cortical bone destruction (bone erosion) or to more 
diffuse changes in the bone marrow space (BME or oste-
itis). The latter lesions have also been described in osteo-
arthritis, spondyloarthritis and systemic lupus erythema-
tosus (54, 62-63).
5. 1. LOCAL BONE LOSS IN 
RHEUMATOID ARTHRITIS
Inflammation in rheumatoid arthritis comprises all 
joint structures, beginning with the synovial membrane 
and propagating to joint capsule, cartilage and juxta-ar-
ticular bone. Increased osteoclast differentiation in rheu-
matoid arthritis occurs at the bone surface/pannus inter-
face as well as within the inflamed synovial tissue (64). 
Due to proximity of inflamed synovial pannus and para-
crine diffusion of proinflammatory cytokines, two shapes 
of bone loss occur locally: focal erosions and subchondral 
bone loss as well as periarticular bone loss (Figure 1).
Most prominent changes of the subchondral compart-
ment include cortical bone erosions, caused by activated 
osteoclasts that migrate from pannus and invade sub-
chondral bone, and diffuse BME adjacent to inflamed 
joints. Focal bone erosions (marginal erosions) develop 
early in disease pathogenesis due to direct contact of pan-
nus and cortical bone surface at the margins of the joint. 
Bone erosions and following joint destruction are hall-
marks of rheumatoid arthritis but also occur in spondylo-
arthritis and the erosive form of osteoarthritis (20). The 
pathohistological correlate of BME is osteitis, with in-
creased vascularization and inflammatory infiltrate (com-
prised of T and B lymphocytes, plasma cells and macro-
phages) replacing marrow fat adjacent to juxta-articular 
trabecular bone. Rheumatoid bone marrow is the site of 
active pathology with histological findings similar to what 
is found within the synovial membrane but with the ad-
dition of active osteoclasts closely juxtaposed to trabecu-
lar bone and likely to be mediating the erosive processes 
(52, 60, 65).
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Periarticular osteopenia is characterized by a decrease 
in trabecular size and number in the metaphyseal regions 
adjacent to the affected joint (66). Periarticular bone loss 
occurs at sites close to inflamed joints but not in direct 
contact with synovial tissue and subchondral lesions. Pre-
sumably, it develops due to an increased local production 
of osteoclast-activating cytokines and their diffusion over 
Haversian and Volkmann canals, leading to excessive 
bone resorption. Decreased loading and reduced motion 
of the limb due to pain and disability contribute to re-
duced BMD. Periarticular demineralization appears ear-
lier than systemic osteoporosis, sometimes even before 
erosions, and can serve as a predictor of greater joint dam-
age (32).
The seronegative spondyloarthropathies (such as pso-
riatic arthritis, ankylosing spondylitis, reactive arthritis 
and arthritis associated with inflammatory bowel dis-
eases) share similarities with some of the local findings in 
rheumatoid arthritis, although distal joints and axial skel-
eton may also be affected. The onset of inflammation is 
at the entheses, where calcification and ossification may 
occur. With the progression of inflammation, bone ero-
sions and bone loss first occur at tendon and ligament 
insertions, and then spread to joint margins, although less 
severe than in rheumatoid arthritis (12).
Rheumatoid synovium, as a rich source of immuno-
modulatory and proinflammatory mediators with osteo-
clastogenic activity, represents the major driving force of 
local bone destruction. The joint structure is invaded by 
the pannus containing a massive infiltrate of immune 
cells, proliferative vessels and an increased number of os-
teoclasts, causing bone degradation. Cytokines abun-
dantly produced by synovial tissue include IL-1, IL-6, 
IL-17 and TNF-a, all of which enhance RANKL-driven 
maturation of osteoclasts from monocyte/macrophage 
progenitors. Therefore, the key factor driving inflamma-
tory bone loss is over-expression of RANKL on synovial 
fibroblasts and infiltrating T lymphocytes. In particular, 
the highly osteoclastogenic Th17 subset of T lymphocytes 
stimulates bone destruction by inducing RANKL expres-
sion on synovial fibroblasts and by, per se, producing 
RANKL in response to IL-6 secreted by synovial fibro-
blasts. In rheumatoid arthritis, RANKL is also produced 
by macrophages, dendritic cells and activated B lympho-
cytes (12, 20, 26, 27). In addition to RANKL upregula-
tion, proinflammatory cytokines enhance osteoclastogen-
esis by enhancing RANK expression on osteoclast 
progenitors and by inducing other proresorptive media-
tors (including M-CSF, PGE2 and other inflammatory 
molecules). Several cytokines (i.e. TNF-a, IL-17, IL-32, 
IL-33) act directly on osteoclast progenitors, thereby in-
ducing osteoclastogenesis by activating crucial differen-
tiation pathways independently of RANKL. By all these 
mechanisms, cytokines induce self-amplifying autocrine 
and paracrine cycles in osteoclast progenitors and mature 
osteoclasts leading to increased osteoclast activation and 
aggressive bone loss (67).
In rheumatoid arthritis, osteoblasts are present at sites 
of bone destruction, but bone repair is absent since their 
low activity fails to compensate for excessive bone resorp-
tion (32). Proinflammatory cytokines (including IL-1, 
IL-6 and TNF-a) are known to suppress osteoblast dif-
ferentiation and bone-matrix production, resulting in 
reduced active mineralizing surfaces in areas of inflam-
mation. Moreover, TNF-a increases production of Dick-
kopf-1 (DKK-1) by synovial fibroblasts, endothelial cells 
and chondrocytes in contact with invading pannus. 
DKK-1 is an inhibitor of Wingless (Wnt) pathway, a sig-
naling cascade involved in osteoblastogenesis. When in-
hibited by DKK-1, osteoblast differentiation is stopped at 
a preosteoblast stage, which impairs bone formation. In-
sufficient osteogenesis is further reinforced by inflamma-
tion-induced activation of nuclear factor-kB in synovial 
mesenchymal cells, promoting their proliferation but in-
hibiting osteoblast/chondroblast lineage differentiation 
(68). Hyperplastic synovial fibroblasts and immature os-
teoblasts highly express RANKL, thus contributing to 
osteoclast differentiation and bone resorption (14).
5.2. GENERALIZED BONE LOSS IN 
RHEUMATOID ARTHRITIS
In addition to local bone loss, rheumatoid arthritis is 
often complicated with generalized osteoporosis in the 
axial and appendicular skeleton (Figure 1). This bone loss 
progresses throughout the disease and correlates with dis-
ease severity, eventually leading to joint deformity and 
increased susceptibility to fractures (14). The presence of 
rheumatoid arthritis increases the risk of fracture inde-
pendently of BMD, even after excluding glucocorticoid-
treated patients, estimated to be approximately 30% 
higher for major osteoporotic fracture (hip, spine, wrist, 
humerus). The causes of increased fractures risk are mul-
tifactorial and include, besides lower BMD, systemic ef-
fects of inflammation on bone remodeling rate and re-
duced physical activity, which leads to impaired mecha nic 
stimulation of bone formation and muscle weakness (64-
66).
Systemic bone loss in the shape of generalized osteo-
porosis is similar in all chronic inflammatory conditions. 
Inflammatory factors such as IL-6 and TNF-a from 
disease-affected sites spill into the circulation proportion-
ally to the intensity of the disease, and affect osteoblast 
and osteoclast differentiation and function. It is of par-
ticular importance that cells with osteoclastogenic poten-
tial, besides bone marrow and synovial compartments, 
also exist in blood and peripheral hematopoietic organs. 
It has been proposed that these peripheral osteoclast pro-
genitors are able to progress into multiple terminally dif-
ferentiated monocyte/macrophage lineage populations, 
and that, under pathological osteoresorptive conditions, 
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they could efficiently home to bone surfaces and mature 
into bone-resorbing osteoclasts (29).
Proinflammatory cytokines such as IL-1, IL-6, TNF-
a and IL-17, released from activated immune cells, target 
osteogenic cells and change their expression profile caus-
ing further production of proinflammatory cytokines and 
chemokines, up-regulation of RANKL expression and 
stimulation of matrix metalloproteinases (64-67). In ad-
dition, some TNF-superfamily members initiate death 
pathways causing increased apoptosis of osteogenic cells, 
resulting in the impaired osteoblast bone formation (4, 
68). Furthermore, proinflammatory cytokines can per-
turb the Wnt and bone morphogenetic protein signaling 
pathways, by the production of DKK-1 and sclerostin, 
leading to aberrant osteoblast differentiation and activity 
(14, 48). In the case of osteoporosis which accompanies 
chronic bacterial infections, circulating bacterial products 
from infection sites affect osteoblasts and osteoclasts by 
interacting with Toll-like and NOD-like receptors, result-
ing in stimulation of osteoclasts and inhibition of osteo-
blasts (4, 66, 69, 70).
Factors that contribute to the development of osteopo-
rosis are, besides chronic inflammation, duration of the 
disease, age of the patient, malnutrition and vitamin de-
ficiency, immobility and pharmacological treatment (glu-
cocorticoids, nonsteroidal-anti-inflammatory drugs, dis-
ease modifying therapy, biological therapy), which can 
have both positive and negative effects on BMD (71). Spe-
cifically glucocorticoids, the most common cause of iat-
rogenic osteoporosis, remain a common treatment option 
for rheumatologic diseases. Glucocorticoids have the 
negative impact on bone by both direct effects on bone 
cells and indirect effect on calcium absorption, resulting 
in reduction of bone formation coupled with persistent 
bone destruction, and increased osteocyte and osteoblast 
apoptosis. Despite a beneficial suppression inflammation, 
the detrimental effects on bone predominate leading to 
increased fragility and fracture risk especially at sites rich 
in trabecular bone (such as the femoral neck and lumbar 
spine). Fracture risk should, therefore, be considered in all 
glucocorticoid-treated patients since it increases within 
the first three months of supraphysiological doses of glu-
cocorticoids and is further heightened by the classical 
osteoporosis risk factors (such as increased age, female sex, 
thin stature, tobacco and alcohol use, and lower BMD) 
(14, 48).
6. CONCLUSION
Studies investigating different chronic inflammatory 
diseases demonstrated the presence of local and systemic 
bone loss, leading to osteoporosis and increased risk of 
fractures and confirming the role of immune system in 
bone remodeling. Bone loss in rheumatoid arthritis, as the 
most studied example of inflammation-induced bone loss, 
is caused by the complex interactions between bone and 
immune cells at the local and systemic levels. Recent stud-
ies suggest that the major pathogenic mechanism, causing 
systemic osteoporosis as well as periarticular bone loss and 
marginal erosions, involves inflammation-induced in-
crease in osteoclast number and activity paralleled by sup-
pressed osteoblast differentiation and function. Although 
it is known that a number of systemic and local stimuli, 
such as hormones and cytokines/chemokines, promote 
osteoresorption by enhancing osteoclast differentiation, 
activation, lifespan and function in inflammatory condi-
tions, further dissection of the molecular mechanisms 
involved in the interactions between immune and bone 
cells is crucial to reveal new findings that could translate 
into effective targeted therapies for inflammatory osteo-
porosis.
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